Global, regional, and national burden and trends of early ‐onset tracheal, bronchus, and lung cancer from 1990 to 2019
ConclusionsAlthough global efforts have been the most successful and effective in reducing the burden of EO-TBL cancer over the past three decades, there was strong regional and gender heterogeneity. EO-TBL cancer need more medical attention in the lower SDI quintiles and in the female population. (Source: Thoracic Cancer)
Source: Thoracic Cancer - February 2, 2024 Category: Cancer & Oncology Authors: Jun Ma, Ying ‐da Song, Xiao‐ming Bai Tags: ORIGINAL ARTICLE Source Type: research

Issue Information
(Source: Thoracic Cancer)
Source: Thoracic Cancer - February 2, 2024 Category: Cancer & Oncology Tags: ISSUE INFORMATION Source Type: research

Peripheral arterial rather than venous blood is a better source of circulating tumor cells in early lung cancer
ConclusionCTC levels in peripheral arterial and venous blood differed little in lung cancer patients.Compared to peripheral venous blood, peripheral arterial blood had a higher CTC positivity rate in early-stage lung cancer.This study was favorable for early detection and monitoring of lung cancer. (Source: Thoracic Cancer)
Source: Thoracic Cancer - February 1, 2024 Category: Cancer & Oncology Authors: Zhen ‐dan Wang, Yi‐fei Feng, Yu‐shuo Wang, Ying Ma, Jiyan Liu, Dihua Li, Sheng Li, Guo‐dong Zhang Tags: ORIGINAL ARTICLE Source Type: research

Prognostic implications of neutrophil ‐to‐lymphocyte ratio in patients with extensive‐stage small cell lung cancer receiving chemoimmunotherapy: A multicenter, real‐world study
ConclusionNLRT2 and irAEs can predict the prognosis of ES-SCLC patients with first-line ES-SCLC receiving PD-L1 inhibitors combined with chemotherapy. (Source: Thoracic Cancer)
Source: Thoracic Cancer - January 31, 2024 Category: Cancer & Oncology Authors: Huanhuan Bi, Dunqiang Ren, Yuting Xiao, Yinxue Zhou, Bingqian Yi, Weizhong Han, Yanmei Shao, Jingluan Wang, Chunling Zhang, Hongmei Wang Tags: ORIGINAL ARTICLE Source Type: research

Robotic ‐assisted bronchoscopy for the diagnosis of peripheral pulmonary lesions: A systematic review and meta‐analysis
In conclusion, RAB is an effective and safe technique for PPLs diagnosis. Further high-quality prospective studies still need to be conducted. (Source: Thoracic Cancer)
Source: Thoracic Cancer - January 30, 2024 Category: Cancer & Oncology Authors: Chunxi Zhang, Fangfang Xie, Runchang Li, Ningxin Cui, Felix J. F. Herth, Jiayuan Sun Tags: REVIEW Source Type: research

Safety of flexible bronchoscopy and clinical course for elderly patients with suspected primary lung cancer
ConclusionsThis study suggests that flexible bronchoscopy can be performed as safely in the elderly as in the nonelderly. Furthermore, even elderly patients may have a greater chance of receiving treatment when a definitive diagnosis is achieved. (Source: Thoracic Cancer)
Source: Thoracic Cancer - January 29, 2024 Category: Cancer & Oncology Authors: Zentaro Saito, Issei Oi, Takanori Ito, Takuma Imakita, Osamu Kanai, Kohei Fujita, Tadashi Mio Tags: ORIGINAL ARTICLE Source Type: research

Efficacy and safety of 40  mg osimertinib administered every other day for non‐small cell lung cancer harboring an epidermal growth factor receptor mutation: A single‐center retrospective cohort study
In this study, we examined the efficacy of 40 mg of osimertinib administered every other day. In this single-center, retrospective study, we evaluated patients with NSCLC harboring anEGFR mutation in whom treatment was initiated with 40  mg osimertinib every other day at our institution between May 2016 and June 2023. The major outcome was the duration of administering 40 mg osimertinib every other day. Six patients with NSCLC were evaluated. The median duration of 40 mg osimertinib intake every other day was 12.6 months. F our of the six patients weighed below 50 kg, and four experienced weight loss. Additiona...
Source: Thoracic Cancer - January 28, 2024 Category: Cancer & Oncology Authors: Ayumu Otsuki, Naoki Inoshima, Kentaro Tochigi, Hiroyuki Ito, Kei Nakashima Tags: BRIEF REPORT Source Type: research

Factors associated with prolonged progression ‐free survival of patients treated with first‐line afatinib for advanced epidermal growth factor receptor‐mutated non‐small cell lung cancer
ConclusionsWe found thatEGFR-mutated NSCLC patients receiving first-line afatinib were prone to shorter PFS if they had distant organ metastasis, especially liver metastasis. (Source: Thoracic Cancer)
Source: Thoracic Cancer - January 27, 2024 Category: Cancer & Oncology Authors: Li ‐Chung Chiu, Ping‐Chih Hsu, Chin‐Chou Wang, How‐Wen Ko, Scott Chih‐Hsi Kuo, Jia‐Shiuan Ju, Pi‐Hung Tung, Allen Chung‐Cheng Huang, Cheng‐Ta Yang Tags: ORIGINAL ARTICLE Source Type: research

Proposed novel grading system for stage I invasive lung adenocarcinoma and a comparison with the 2020 IASLC grading system
ConclusionThe newly proposed grading system based on four pathological factors (presence of STAS, and percentage of lepidic, micropapillary, and solid subtypes) exhibits high accuracy and good reproducibility in the prognostic stratification of stage I lung adenocarcinoma patients. (Source: Thoracic Cancer)
Source: Thoracic Cancer - January 26, 2024 Category: Cancer & Oncology Authors: Shuaibo Wang, Ye Li, Xujie Sun, Jiyan Dong, Li Liu, Jingbo Liu, Ruanqi Chen, Feng Li, Tiange Chen, Xiang Li, Guotong Xie, Jianming Ying, Qiang Guo, Yousheng Mao, Lin Yang Tags: ORIGINAL ARTICLE Source Type: research

Prognostic value and relapse pattern of HER2 ‐low in hormone receptor‐positive breast cancer
ConclusionsNo significant difference in DFS and OS between the HER2-low group and the HER2-zero group was observed. Patients with HER2 IHC 1+ and 0 tend to develop bone metastasis. The HER2-low group had a more obvious second peak in mortality. (Source: Thoracic Cancer)
Source: Thoracic Cancer - January 26, 2024 Category: Cancer & Oncology Authors: Tong Wei, Yikun Kang, Xue Wang, Jian Yue, Binghe Xu, Peng Yuan Tags: ORIGINAL ARTICLE Source Type: research

Triptolide inhibits esophageal squamous cell carcinoma progression by regulating the circNOX4/miR ‐153‐3p/SATB1 signaling pathway
ConclusionTriptolide could hinder ESCC progression, which was mainly achieved by regulating the circNOX4/miR-153-3p/SATB1 axis. (Source: Thoracic Cancer)
Source: Thoracic Cancer - January 25, 2024 Category: Cancer & Oncology Authors: Hanping Liang, Weibi Che, Fengyuan Peng, Huilong Chen, Xihao Xie, Bomeng Wu Tags: ORIGINAL ARTICLE Source Type: research

Implication of IZUMO2 in the cell ‐in‐cell phenomenon: A potential therapeutic target for triple‐negative breast cancer
ConclusionThe findings highlight the importance of IZUMO2 on TNBC cells in facilitating the cell-in-cell phenomenon by A-Tregs. (Source: Thoracic Cancer)
Source: Thoracic Cancer - January 23, 2024 Category: Cancer & Oncology Authors: Toshiya Higashi, Chiemi Saigo, Wakana Chikaishi, Hirokatsu Hayashi, Yuki Hanamatsu, Manabu Futamura, Nobuhisa Matsuhashi, Tamotsu Takeuchi Tags: ORIGINAL ARTICLE Source Type: research

Issue Information
(Source: Thoracic Cancer)
Source: Thoracic Cancer - January 23, 2024 Category: Cancer & Oncology Tags: ISSUE INFORMATION Source Type: research

Relationship between patterns of immunohistochemical conventional neuroendocrine markers and efficacy of immune check point inhibitors in patients with extensive disease small cell lung cancer
ConclusionOur study suggests that the efficacy of ICIs in addition to chemotherapy may be poor in patients with NE marker-negative SCLC. (Source: Thoracic Cancer)
Source: Thoracic Cancer - January 20, 2024 Category: Cancer & Oncology Authors: Yuko Iida, Kazushige Wakuda, Takuya Kawata, Meiko Morita, Motoki Sekikawa, Kosei Doshita, Michitoshi Yabe, Hiroaki Kodama, Keita Miura, Noboru Morikawa, Nobuaki Mamesaya, Haruki Kobayashi, Ryo Ko, Akira Ono, Hirotsugu Kenmotsu, Tateaki Nait Tags: ORIGINAL ARTICLE Source Type: research

Real ‐world survival outcomes of immunotherapy for advanced non‐small cell lung cancer: A single‐center retrospective review
ConclusionReal-world survival outcomes of immunotherapy for advanced NSCLC are comparable to the existing literature in this single center study. (Source: Thoracic Cancer)
Source: Thoracic Cancer - January 19, 2024 Category: Cancer & Oncology Authors: Gopika Punchhi, Abdulkadir Hussein, Swati Kulkarni Tags: ORIGINAL ARTICLE Source Type: research